The United States Food and Drug Administration announced on May 4 that it had sent warning letters to five American companies illegally selling cannabidiol (CBD) and Delta-8 THC products that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA focused mainly on the marketing and distribution of Delta-8 THC, stating that there are currently no FDA-approved drugs containing the compound. 

Related Article: Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies

Beginning a Crackdown on Delta-8 Commercialization

The FDA has issued warning letters to many companies in the last several years regarding CBD commercialization. Still, the FDA’s most recent warning to five companies is the first time it has issued warnings regarding Delta-8. The FDA mentioned in yesterday’s warning that one of the concerns is the illegal marketing of Delta-8 for medicinal uses, despite not being FDA approved.